Could a 'Female Viagra' drug boost libido in men on prostate cancer treatment?

NCT ID NCT04743934

Completed Symptom relief Sponsor: Andrew McDonald Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase II trial tests whether flibanserin, a drug approved for low sexual desire in women, can increase sexual interest in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). About 44 men will be randomly assigned to take flibanserin or a placebo daily at bedtime. The study measures how often participants attempt sexual intercourse and their sexual quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flibanserin, a drug taken daily at bedtime
What this could lead to: If it works, this could offer a way to improve sexual interest and quality of life for men undergoing hormone therapy for prostate cancer.
What could go wrong: This is a small, early-phase trial, so results may not be conclusive. Flibanserin is not approved for men and may cause side effects like dizziness or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.